Moderna‘s COVID-19 booster shot “can be considered” in those aged above 18, the European Medicines Agency, a major drug regulator for the European Union, said on Monday.

According to an analytical report presented by the drug agency in a statement, the Moderna vaccine showed signs of boosted antibody levels in adults when administered at least six months after the previous shot.

The company cuts the amount of vaccine in half for the booster shot. Moderna’s COVID-19 vaccine — in the initial inoculation– is given in a two-shot series.

According to reports from Associated Press citing the European Medicines Agency, the current data suggests that the side effects triggered by the booster dose of Moderna — temporary heart and chest inflammation– are similar to those of the second shot. 

Also Read: FDA says Pfizer COVID vaccine effective for kids

The statement read, “At national level, public health bodies may issue official recommendations on the use of booster doses, taking into account the local epidemiological situation”, according to reports from Associated Press.

A similar ruling was given by the European Medicines Agency earlier this month for the booster dosage of Pfizer’s COVID-19 vaccine. The drug agency has also backed the pharmaceutical giant’s vaccine for the third dose for people with compromised immune systems.

Booster doses of the vaccines made by Pfizer-BioNTech and Moderna have already been authorized by American officials, but there are still restrictions on who qualifies.

Starting six months past their last Pfizer or Moderna vaccination, people are urged to get a booster if they’re 65 or older, nursing home residents, or at least 50 and at increased risk of severe disease because of health problems.

Boosters also were allowed, but not urged, for adults of any age at increased risk of infection because of health problems or their jobs or living conditions. That includes health care workers, teachers and people in jails or homeless shelters.